Reports Q2 revenue $8.05M, consensus $7.97M. “We continued to see growth during the second quarter, with net FUROSCIX revenue of $8.1 million on approximately 9,300 doses filled, representing sequential growth of 33% and 15%, respectively, from the first quarter 2024,” stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals. “Notably, we believe that all of our leading indicators continue to reflect growing acceptance of FUROSCIX as a key part of a new heart failure treatment paradigm.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- scPharmaceuticals sells 12M shares at $4.00 in public offering
- scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
- scPharmaceuticals Secures Funding, Advances FUROSCIX Commercialization
- scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure